연구동향 분석
박사

Pathophysiological role of Toll like receptor 4 in mast cells in a rat model of atopic dermatitis

김희주 2015년

논문상세정보
인용/피인용
' Pathophysiological role of Toll like receptor 4 in mast cells in a rat model of atopic dermatitis' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • atopic dermatitis
  • atopic dermatitis rat model
  • mast cell
  • pruritus
  • toll like receptor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
333 0

0.0%

' Pathophysiological role of Toll like receptor 4 in mast cells in a rat model of atopic dermatitis' 의 참고문헌

  • Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and theirbiological significance. J Cell Mol Med 2010;14:2592-603.
  • Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003;361:690-4.
  • Yang C, Mo X, Lv J, et al. Lipopolysaccharide enhances FcepsilonRImediatedmast cell degranulation by increasing Ca2+ entry through storeoperatedCa2+ channels: implications for lipopolysaccharide exacerbatingallergic asthma. Exp Physiol 2012;97:1315-27.
  • West XZ, Malinin NL, Merkulova AA, et al. Oxidative stress inducesangiogenesis by activating TLR2 with novel endogenous ligands. Nature2010;467:972-6.
  • Werfel T. The role of leukocytes, keratinocytes, and allergen-specific IgEin the development of atopic dermatitis. J Invest Dermatol 2009;129:1878-91.
  • Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations withinthe filaggrin gene predispose for atopic dermatitis with allergicsensitizations. J Allergy Clin Immunol 2006;118:214-9.
  • Wahlgren CF. Itch and atopic dermatitis: an overview. J Dermatol1999;26:770-9.
  • Varadaradjalou S, Feger F, Thieblemont N, et al. Toll-like receptor 2(TLR2) and TLR4 differentially activate human mast cells. Eur J Immunol2003;33:899-906.48
  • Tsan MF, Gao B. Endogenous ligands of Toll-like receptors. J Leukoc Biol2004;76:514-9.
  • Tong L, Corrales RM, Chen Z, et al. Expression and regulation of cornifiedenvelope proteins in human corneal epithelium. Invest Ophthalmol Vis Sci2006;47:1938-46.
  • Suzuki R, Furuno T, McKay DM, et al. Direct neurite-mast cellcommunication in vitro occurs via the neuropeptide substance P. J Immunol1999;163:2410-5.51
  • Supajatura V, Ushio H, Nakao A, et al. Differential responses of mast cellToll-like receptors 2 and 4 in allergy and innate immunity. J Clin Invest2002;109:1351-9.
  • Steinert PM, Marekov LN. The proteins elafin, filaggrin, keratinintermediate filaments, loricrin, and small proline-rich proteins 1and 2 are isodipeptide cross-linked components of the humanepidermal cornified cell envelope. J Biol Chem 1995;270:17702-11.
  • Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: anoverview. Exp Dermatol 2002;11:12-24.
  • Simon D, Braathen LR, Simon HU. Increased lipopolysaccharide-inducedtumour necrosis factor-alpha, interferon-gamma and interleukin-10production in atopic dermatitis. Br J Dermatol 2007;157:583-6.50
  • Segre JA. Epidermal barrier formation and recovery in skin disorders. J ClinInvest 2006;116:1150-8.
  • Scott RS, McMahon EJ, Pop SM, et al. Phagocytosis and clearance ofapoptotic cells is mediated by MER. Nature 2001;411:207-11.55
  • Saluja R, Delin I, Nilsson GP, et al. FcepsilonR1-mediated mast cellreactivity is amplified through prolonged Toll-like receptor-ligandtreatment. PLoS One 2012;7:e43547.52
  • Paus R, Schmelz M, Biro T, et al. Frontiers in pruritus research: scratchingthe brain for more effective itch therapy. J Clin Invest 2006;116:1174-86.
  • Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cellsinitiate psoriasis through interferon-alpha production. J Exp Med2005;202:135-43.
  • Mrabet-Dahbi S, Metz M, Dudeck A, et al. Murine mast cells secrete aunique profile of cytokines and prostaglandins in response to distinct TLR2ligands. Exp Dermatol 2009;18:437-44.
  • Morar N, Cookson WO, Harper JI, et al. Filaggrin mutations in children withsevere atopic dermatitis. J Invest Dermatol 2007;127:1667-72.
  • Mihara K, Kuratani K, Matsui T, et al. Vital role of the itch-scratchresponse in development of spontaneous dermatitis in NC/Nga mice. Br JDermatol 2004;151:335-45.
  • Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenousactivator of Toll-like receptor 4 that is essential for maintaininginflammation in arthritic joint disease. Nat Med 2009;15:774-80.
  • Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77:1033-79.
  • Means TK, Luster AD. Toll-like receptor activation in the pathogenesis ofsystemic lupus erythematosus. Ann N Y Acad Sci 2005;1062:242-51.
  • McCurdy JD, Lin TJ, Marshall JS. Toll-like receptor 4-mediated activationof murine mast cells. J Leukoc Biol 2001;70:977-84.
  • Masuda A, Yoshikai Y, Aiba K, et al. Th2 cytokine production from mastcells is directly induced by lipopolysaccharide and distinctly regulated byc-Jun N-terminal kinase and p38 pathways. J Immunol 2002;169:3801-10.
  • Marshall JS, McCurdy JD, Olynych T. Toll-like receptor-mediatedactivation of mast cells: implications for allergic disease? Int Arch AllergyImmunol 2003;132:87-97.
  • Lu Z, Zhang X, Li Y, et al. TLR4 antagonist reduces early-stageatherosclerosis in diabetic apolipoprotein E-deficient mice. J Endocrinol2013;216:61-71.
  • Liu T, Gao YJ, Ji RR. Emerging role of Toll-like receptors in the control ofpain and itch. Neurosci Bull 2012;28:131-44.
  • Liu T, Berta T, Xu ZZ, et al. TLR3 deficiency impairs spinal cord synaptictransmission, central sensitization, and pruritus in mice. J Clin Invest2012;122:2195-207.
  • Lin L, Penaloza C, Ye Y, et al. Detection of apoptosis in mammaliandevelopment. Methods Mol Biol 2009;559:259-72.49
  • Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role ofmicroglia in Toll-like receptor-mediated neuronal injury. Glia 2010;58:253-63.
  • Kim D, Kim MA, Cho IH, et al. A critical role of toll-like receptor 2 in nerveinjury-induced spinal cord glial cell activation and pain hypersensitivity. JBiol Chem 2007;282:14975-83.
  • Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr OpinImmunol 2005;17:338-44.
  • Kang SS, Kauls LS, Gaspari AA. Toll-like receptors: applications todermatologic disease. J Am Acad Dermatol 2006;54:951-83; quiz 83-6.
  • Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a majorgene for atopic dermatitis. J Invest Dermatol 2006;126:1200-2.
  • Ikoma A, Steinhoff M, Stander S, et al. The neurobiology of itch. Nat RevNeurosci 2006;7:535-47.
  • Hammad H, Chieppa M, Perros F, et al. House dust mite allergen inducesasthma via Toll-like receptor 4 triggering of airway structural cells. NatMed 2009;15:410-6.
  • Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine geneexpression in acute versus chronic atopic dermatitis. J Clin Invest1994;94:870-6.
  • Hafenreffer S. Nosodochium, in quo cutis, eique adhaerentium partium,affectus omnes, singulari methodo, et cognoscendi et curandi ... traduntur;quod etiam variis medicamentis Galencis, chymicis, cosmeticis ... estillustratum ... sub calcem adjecti tibicines, lectorem, Arabica, Graeca, Latina& Germanica contenta, indagare succincte informant. Renovatum & plurimisin locis auctum. Ulmae,: Typis & expensis Balthasar. Kuhnen; 1660.
  • Greaves M. Mast cell mediators other than histamine induced pruritus inatopic dermatitis patients - a dermal microdialysis study. Br J Dermatol2000;142:1079-80.47
  • Gessner A, Mohrs K, Mohrs M. Mast cells, basophils, and eosinophilsacquire constitutive IL-4 and IL-13 transcripts during lineagedifferentiation that are sufficient for rapid cytokine production. J Immunol2005;174:1063-72.
  • Geng S, Gao YD, Yang J, et al. Potential role of store-operated Ca2+ entryin Th2 response induced by histamine in human monocyte-derived dendriticcells. Int Immunopharmacol 2012;12:358-67.56
  • Galli SJ, Gordon JR, Wershil BK. Cytokine production by mast cells andbasophils. Curr Opin Immunol 1991;3:865-72.
  • Gaipl US, Franz S, Voll RE, et al. Defects in the disposal of dying cells leadto autoimmunity. Curr Rheumatol Rep 2004;6:401-7.
  • Finlay AY. Quality of life in atopic dermatitis. J Am Acad Dermatol2001;45:S64-6.
  • Erridge C. Endogenous ligands of TLR2 and TLR4: agonists or assistants? JLeukoc Biol 2010;87:989-99.
  • Elliott MR, Ravichandran KS. Clearance of apoptotic cells: implications inhealth and disease. J Cell Biol 2010;189:1059-70.
  • Eichenfield LF, Hanifin JM, Luger TA, et al. Consensus conference onpediatric atopic dermatitis. J Am Acad Dermatol 2003;49:1088-95.
  • Cocchiara R, Lampiasi N, Albeggiani G, et al. Mast cell production of TNFalphainduced by substance P evidence for a modulatory role of substanceP-antagonists. J Neuroimmunol 1999;101:128-36.
  • Charlesworth EN, Beltrani VS. Pruritic dermatoses: overview of etiologyand therapy. Am J Med 2002;113 Suppl 9A:25S-33S.
  • Chang WC, Lee CH, Hirota T, et al. ORAI1 genetic polymorphismsassociated with the susceptibility of atopic dermatitis in Japanese andTaiwanese populations. PLoS One 2012;7:e29387.
  • Bieber T. Atopic dermatitis. N Engl J Med 2008;358:1483-94.54
  • Barker JN, Palmer CN, Zhao Y, et al. Null mutations in the filaggrin gene(FLG) determine major susceptibility to early-onset atopic dermatitis thatpersists into adulthood. J Invest Dermatol 2007;127:564-7.53
  • Back SK, Jeong KY, Li C, et al. Chronically relapsing pruritic dermatitis inthe rats treated as neonate with capsaicin; a potential rat model of humanatopic dermatitis. J Dermatol Sci 2012;67:111-9.
  • Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens.Nat Rev Immunol 2010;10:440-52.